GKOS is currently developing the following drugs: Glk-321 Low Dose Bid, Glk-321 Mid Dose Bid, Glk-321 High Dose Bid, Glk-321 High Dose Qd, Sham Procedure, Gen 2 Travoprost Intracameral Implant, Timolol Eye Drops 0.5%, Idose Tr 75 Μg In Conjunction With Cataract Surgery, Sham Procedure In Conjunction With Cataract Surgery. These drug candidates are in various stages of clinical development as the company works toward FDA approval.